Nika Pharmaceuticals Reports Q3 2025 Financial Results with Improved Net Loss

Nika Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $7,999 for the three months ended September 30, compared to a loss of $8,367 for the same period in 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $39,309, a significant improvement from the $83,340 loss reported in the prior year. The company did not generate any revenue during this period, and its total operating expenses decreased to $39,309 from $83,340 year-over-year, primarily due to reduced general and administrative costs.

The company's total assets increased to $23,625 as of September 30, 2025, up from $17,934 at the end of 2024. This growth was driven by a rise in cash reserves, which reached $6,287, compared to $2,083 at the end of the previous fiscal year. However, total liabilities also increased, with current liabilities rising to $284,164 from $239,164, largely due to amounts owed to related parties. The stockholders' deficit widened to $260,539 from $221,230, reflecting ongoing operational losses.

Strategically, Nika Pharmaceuticals has been active in expanding its business operations. The company completed a merger with Nika BioTechnology, Inc. in April 2024, which enhanced its controlling interest in Nika Europe, Ltd. to 80%. This merger is expected to bolster Nika's presence in European, Asian, and African markets. Additionally, the company has entered into several exclusive rights agreements for the production and distribution of various pharmaceutical products, including Thymus Nuclear Glycoprotein and dietary supplements, which are anticipated to contribute to future revenue streams.

Operationally, Nika Pharmaceuticals has not reported significant changes in customer counts or user statistics, as the company is still in the early stages of product development and market entry. The company has focused on establishing its manufacturing capabilities, with plans for a pharmaceutical factory in Bulgaria that will support its production needs. As of September 30, 2025, the company had a total of 1,039,836,001 shares of common stock outstanding, reflecting an increase from the previous year, which may indicate a strategy to raise capital through equity.

Looking ahead, Nika Pharmaceuticals acknowledges substantial doubt about its ability to continue as a going concern, given its accumulated deficit of $8,966,920 and lack of revenue. The company plans to explore additional capital-raising opportunities, including potential mergers with operating entities, to support its business objectives. However, the success of these strategies remains uncertain, and the company has not included any adjustments in its financial statements that might arise from this uncertainty.